Correction: J Exp Clin Cancer Res 40, 320 (2021)
https://doi.org/10.1186/s13046-021-02127-x
Following publication of the original article [1], the authors identified an error in Fig. 6. The image representative of cell nuclei (DAPI staining) of the group “control” (panel “b”, first on the left) was unintentionally duplicated in panel “c” relative to the group “oxaliplatin” during the image assembly process by the authors.
The correction does not alter the scientific outcome since the result about the colocalization analysis of VEGF-A and GFAP in control and oxaliplatin-treated mice did not require the use of DAPI channel. The original article [1] has been corrected.
Incorrect Fig. 6
Fig. 6.
VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy. (a) Representative images and quantitative analysis of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control animals (vehicle, n = 13). (b-d) Colocalization analysis of VEGF-A and GFAP in control (b) and oxaliplatin-treated mice (c). Quantitative analysis of colocalization area (d) (vehicle, n = 13; oxaliplatin, n = 12). Scale bar: 100 μm; insert: 50 μm. Each value represents the mean ± SEM. *P < 0.05 vs vehicle group. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison
Correct Fig. 6
Fig. 6.
VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy. (a) Representative images and quantitative analysis of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control animals (vehicle, n = 13). (b-d) Colocalization analysis of VEGF-A and GFAP in control (b) and oxaliplatin-treated mice (c). Quantitative analysis of colocalization area (d) (vehicle, n = 13; oxaliplatin, n = 12). Scale bar: 100 μm; insert: 50 μm. Each value represents the mean ± SEM. *P < 0.05 vs vehicle group. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison
Footnotes
Laura Micheli and Carmen Parisio contributed equally to this work.
Contributor Information
Grazia Graziani, Email: graziani@uniroma2.it.
Lorenzo Di Cesare Mannelli, Email: lorenzo.mannelli@unifi.it.
Reference
- 1.Micheli L, Parisio C, Lucarini E, et al. VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. J Exp Clin Cancer Res. 2021;40:320. doi: 10.1186/s13046-021-02127-x. [DOI] [PMC free article] [PubMed] [Google Scholar]